Skip to main content
Home
Latest news
Browse topics
Cardiovascular disorders Chronic kidney disease Diabetes devices & technology GLP-1 receptor agonists Hyperglycemia Hypoglycemia Obesity, diet, & lifestyle interventions SGLT2 inhibitors Type 1 diabetes Type 2 diabetes Browse all topics
EN
EN
In focus
Novel clinical evidence in continuous glucose monitoring Fasting for religion and health in people with diabetes The challenge of type 2 diabetes in children HFpEF & diabetes: Diagnosis and management in the wake of EMPEROR-Preserved Addressing suicide risk in diabetes: Rates and risk factors, HCP fears, and practical advice The SURPASS trials: Summarizing efficacy data on tirzepatide Semaglutide for weight loss: STEP and SELECT trials: Results from the STEP and SELECT trials Why psychosocial care matters DiRECT: Type 2 diabetes remission through weight management
Congress coverage
EASD 58th Annual Meeting 2022 The American Diabetes Association 82nd Scientific Sessions
About us
Medicine Matters Diabetes
EXTENDED SEARCH

Flash glucose monitoring technology: Downloadable slide sets from key studies and clinical trials in people with diabetes

Real-world evidence

Three European retrospective real-world chart review studies to determine the effectiveness of flash glucose monitoring on HbA1c in adults with type 2 diabetes

This slide set details a chart-review study involving three European countries, showing significantly reduced glycated hemoglobin in adults with insulin-dependent type 2 diabetes after 3 to 6 months of flash glucose monitoring. 
Source: Kröger J, Fasching P, Hanaire H. Diabetes Ther 2020; 11: 279–291

Funded by an educational grant from Abbott Diabetes Care

View or download here

The impact of flash glucose monitoring on glycaemic control as measured by HbA1c: a meta-analysis of clinical trials and real-world observational studies

These slides describe a meta-analysis of randomized trials and real-world studies, confirming reductions in glycated hemoglobin in children and adults with type 1 diabetes and adults with type 2 diabetes using flash glucose monitoring. 
Source: Evans M, Welsh Z, Ells S, Seibold A. Diabetes Ther 2020; 11: 83–95 

Funded by an educational grant from Abbott Diabetes Care

VIew or download here

Randomized control trial evidence

An alternative sensor-based method for glucose monitoring in children and young people with diabetes

These slides detail a study of flash glucose monitoring in children and adolescents, showing good accuracy relative to capillary blood glucose testing during up to 14 days of use, along with high acceptability of the device. 
Source: Edge J, Acerini C, Campbell F, et al. Arch Dis Child 2017; 102: 543–549

Funded by an educational grant from Abbott Diabetes Care

Outcomes of using flash glucose monitoring technology by children and young people with type 1 diabetes in a single arm study

The study outlined in this slide set showed improved time in optimal blood glucose range and greater treatment satisfaction among children and adolescents with type 1 diabetes using flash glucose monitoring compared with self-monitoring. 
Source: Campbell FM, Murphy NP, Stewart C, Biester T, Kordonouri O. Pediatr Diabetes 2018; 19: 1294–1301

Funded by an educational grant from Abbott Diabetes Care

Accuracy, user acceptability, and safety evaluation for the FreeStyle Libre flash glucose monitoring system when used by pregnant women with diabetes

This slide set describes a study of flash glucose monitoring in pregnant women with diabetes, which demonstrates clinical accuracy versus self-monitoring of blood glucose and a high level of acceptability by the patients.
Source: Scott EM, Bilous RW, Kautzky-Willer A. Diabetes Technol Ther 2018; 20: 180–188

Funded by an educational grant from Abbott Diabetes Care

Use of flash glucose-sensing technology for 12 months as a replacement for blood glucose monitoring in insulin-treated type 2 diabetes

This slide set outlines the extension phase of the REPLACE trial, which shows that the significant reductions in hypoglycemia obtained in patients with insulin-dependent type 2 diabetes after 6 months of flash glucose monitoring use were sustained over an additional 6 months. 
Source: Haak T, Hanaire H, Ajjan R, Hermanns N, Riveline JP, Rayman G. Diabetes Ther 2017; 8: 573–586

Funded by an educational grant from Abbott Diabetes Care

View more slide sets from the archive

Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial

This slide set presents trial findings showing that patients with well-controlled type 1 diabetes who undergo flash glucose testing achieve a greater reduction in the time spent in hypoglycemia over 6 months than those who carry out standard self-monitoring. 
Source: Bolinder J, Antuna R, Geelhoed-Duijvestijn P, et al. Lancet 2016; 388: 2254–2263

Funded by an educational grant from Abbott Diabetes Care
 

Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated type 2 diabetes: a multicenter, open-label randomized controlled trial

This slide set outlines the results of an open-label trial suggesting that the use of flash glucose-sensing technology results in similar changes in glycated hemoglobin over 6 months compared with standard self-monitoring among insulin-treated patients with type 2 diabetes. 
Source: Haak T, Hanaire H, Ajjan R, et al. Diabetes Ther 2017; 8: 55–73

Funded by an educational grant from Abbott Diabetes Care

Impact of flash glucose monitoring on hypoglycaemia in adults with type 1 diabetes managed with multiple daily injection therapy: a pre-specified subgroup analysis of the IMPACT randomised controlled trial

This slide set describes the results of a subgroup analysis of the IMPACT study, which demonstrates that the use of flash glucose technology is associated with a significant reduction in the time spent in hypoglycemia among patients with well-controlled type 1 diabetes treated with multiple daily injections.
Source: Oskarsson P, Antuna R, Geelhoed-Duijvestijn P, et al. Diabetologia 2018; 61: 539–550

Funded by an educational grant from Abbott Diabetes Care

Image Credits